27 February 2026

Update on the phase 2a reALIS study with adimanebart in people with ALS

Today, argenx shares an important update on the adimanebart Phase 2a reALISe study in people living with ALS.

While adimanebart was well tolerated and showed a favorable safety profile, the results do not support advancing the program to the next stage of development due to the absence of treatment effect on secondary and exploratory endpoints.

Argenx shares this disappointment with the ALS community who have seen many setbacks across the industry. While this study did not show the outcome we hoped for, we hope that the data will help contribute to the collective scientific understanding of ALS. We remain committed to engaging with the community as the field continues to explore new approaches to this disease.

We are extremely grateful to the patients who participated in this study . The discussions we held with trial participants have been invaluable in learning about patient perspectives and help further refine our approach to drug development.

Source: argenx